medric medric
[닫기]
잠시만 기다려 주세요. 로딩중입니다.

Oncologic Outcomes of Stage IIIA Colon Cancer for Different Chemotherapeutic Regimens

대한대장항문학회지 2012년 28권 5호 p.259 ~ 264
이유성 ( Lee Yoo-Sung ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Surgery

 ( Kim Hee-Cheol ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Surgery
 ( Jung Kyung-OoK ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Surgery
 ( Cho Yong-Beom ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Surgery
 ( Yun Seong-Hyeon ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Surgery
 ( Lee Woo-Yong ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Surgery
 ( Chun Ho-Kyung ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Surgery

Abstract


Purpose: Adjuvant chemotherapy is currently recommended for Stage IIIA colon cancers. This study aimed to elucidate the oncologic outcomes of Stage IIIA colon cancer according to the chemotherapeutic regimen based on a retrospective review.

Methods: From 1995 to 2008, Stage IIIA colon cancer patients were identified from a prospectively maintained database at a single institution. Exclusion criteria were as follows: rectal cancer, another malignancy other than colon cancer, no adjuvant chemotherapy and unknown chemotherapeutic regimen. One hundred thirty-one patients were enrolled in the study, and the clinicopathologic and the oncologic characteristics were analyzed. The number of males was 72, and the number of females was 59; the mean age was 59.5 years (range, 25 to 76 years), and the median follow-up period was 33 months (range, 2 to 127 months).

Results: Of the 131 patients, fluorouracil/leucovorin (FL)/capecitabine chemotherapy was performed in 109 patients, and FOLFOX chemotherapy was performed in 22 patients. When the patients who received FL/capecitabine chemotherapy and the patients who received FOLFOX chemotherapy were compared, there was no significant difference in the clinicopathologic factors between the two groups. The 5-year overall survival and the 5-year disease-free survival were 97.2% and 94.5% in the FL/capecitabine patient group and 95.5% and 90.9% in the FOLFOX patient group, respectively, and no statistically significant differences were noted between the two groups.

Conclusion: Stage IIIA colon cancer showed good oncologic outcomes, and the chemotherapeutic regimen did not seem to affect the oncologic outcome.

키워드

Stage IIIA; Colon neoplasm; Chemotherapeutic agent; Prognosis
원문 및 링크아웃 정보
  
등재저널 정보
KCI
KoreaMed
KAMS